Actavis Watson QRxPharma Inventiv Health....

Quote
















































update:

Since QRx is highly dependent on MoxDuo, I expect that the FDA decision regarding MoxDuo IR will have tremendous impact on the price of shares. A clean approval could cause shares to continue another leg in their multi-year rally, perhaps going as high as $3/share. On the other hand, a rejection could bring up fears over the true efficacy of the viability morphine/oxycodone and spark a major selloff which could send shares into a ditch for a quite some time. So, for the most part, QRXPY is simply a high-stakes gamble in the FDA’s decision on June 25th.

Nothing yet.
 












safety concerns which isn't surprising cuz per abuse with narcotics and fda has been brutal! this is third time in six months that a great drug wasnt approved.

sorry for everyone awaiting decision
 






Top Bottom
Back
Quote